Skip to main content
ACRS
NASDAQ Life Sciences

Aclaris Therapeutics Reports Positive Phase 1A Results for ATI-052, Plans Phase 2B in Asthma

Tom Rudovsky · Reported by Reuters
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.73
Mkt Cap
$531.825M
52W Low
$1.16
52W High
$4.89
52W Position info
308% above low
Off High info
3.3% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ACRS has more than doubled off its 52-week low of $1.16.

Summary

Aclaris Therapeutics announced positive full top-line first-in-human results from its Phase 1A clinical trial of ATI-052, a novel anti-TSLP/IL-4Rα bispecific antibody. The trial demonstrated that ATI-052 was well-tolerated with a favorable safety profile, and no impact of anti-drug antibodies on PK or PD was observed. This positive early-stage data is a significant de-risking event for the program, which the company plans to advance into a Phase 2B program for asthma in Q4 2026. Enrollment is also ongoing for Phase 1B trials of ATI-052, with top-line results expected in the second half of 2026. This news provides a strong positive catalyst for the stock, validating its pipeline and potentially attracting further investor interest.

At the time of this announcement, ACRS was trading at $4.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $531.8M. The 52-week trading range was $1.16 to $4.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ACRS - Latest Insights

ACRS
Nov 16, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $3.44 info
Change: +$0.160 (+5%) info
Market Cap: $545.626M info
ACRS
Nov 16, 2026, 3:28 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $3.44 info
Change: -$0.320 (-9%) info
Market Cap: $545.626M info
ACRS
Nov 05, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.44 info
Change: -$0.170 (-5%) info
Market Cap: $545.626M info
ACRS
Nov 05, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.44 info
Change: -$0.170 (-5%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.44 info
Change: -$0.280 (-8%) info
Market Cap: $545.626M info